ClinicalTrials.gg
Not yet recruitingNCT04347967Updated Dec 4, 2023

Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS)

A Phase 1 interventional study of UMC119-06 in Acute Respiratory Distress Syndrome, sponsored by Meridigen Biotech Co., Ltd.. Not yet recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-12-04.

Sponsored by Meridigen Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Respiratory Distress Syndrome with a site in Taiwan — 7 open to participants now, 7 under way, 1 of them phase 3. Respiratory Distress Syndrome · Taiwan.

Planned enrollment
18th of 18
18 · median 74
Started
2024
with 2 others
Phase 1
2 of 28
2 open now
Registered
18th of 28
by date

Among the 28 studies in Respiratory Distress Syndrome with a site in Taiwan, this one is the 18th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2024, is one of 2 in phase 1, and was the 18th registered.

Respiratory Distress Syndrome

1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

7 of the 28 studies in Respiratory Distress Syndrome with a site in Taiwan are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 193 Respiratory Distress Syndrome studies recruiting now, 117 (61%) set no upper age limit and 48 (25%) stop at 75 or younger; 50 take children under 18; 9 take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Respiratory Distress Syndrome with a site in Taiwan, or all of them as a file.
02

Study summary

The clinical study with UMC119-06 is designed to investigate the safety in patients with moderate acute respiratory distress syndrome ("ARDS"). This will be a dose escalation, open-label, single-center study in adult with ARDS. UMC119-06 is ex vivo cultured human umbilical cord derived mensenchymal stem cells (hUC-MSCs) product which is intended for treatment of ARDS.

Read the detailed description

ARDS, a noncardiogenic respiratory disease, is characterized by progressive hypoxemia and respiratory distress, associated with explosive acute inflammation and alveolar edema. ARDS occurs in all age group of patients, where mortality rates increase in advancing age.

In animal studies of ARDS, mensenchymal stem cells (MSCs) can attenuate lipopolysaccharides (LPS)-induced lung injury and pulmonary permeability edema through modulating the inflammatory. These findings show that MSCs may improve the clinical outcomes and prognosis of ARDS patient. Meridigen is developing UMC119-06, human umbilical cord-derived MSCs, for the treatment of ARDS. The purpose of this study is to assess the safety of UMC119-06 in patients with ARDS.

03

Conditions studied

  • Acute Respiratory Distress Syndrome

Keywords

  • ARDS
04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects of age ≥ 20 years and ≤ 85 years.
  • Subject has a diagnosis of moderate ARDS according to the Berlin definition of ARDS:

    1. No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.
    2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph.
    3. Hypoxemia: PaO2/ FiO2 > 100 mmHg to ≤ 200 mmHg with PEEP ≥ 5 cm H2O.
    4. The time of onset of ARDS is when all of the specified ARDS criteria (2a-c) are met.
  • Patient is intubated and mechanically ventilated.
  • Subjects who had an onset of ARDS within 72 to 120 hours before start of treatment.
  • Subjects with body weight between 40 to 90 kg.
  • No decompensated heart failure.
  • Subject is willing to provide written to participate in the study after reading the informed consent form and the information provided.
  • Women of should have a negative serum pregnancy test prior to administration of product., UNLESS they meet the following criteria:

    1. : 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum Follicle Stimulating Hormone (FSH) levels > 40 mIU/ml, OR;
    2. 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy.

Exclusion criteria

Exclusion Criteria:

  • Greater than 72 hours since first meeting ARDS criteria per the Berlin definition.
  • No intent/unwillingness to follow lung protective ventilation strategy or fluid management protocol.
  • Expected life \< 3 months from other cause than the respiratory failure.
  • Subject is receiving extra-corporeal membrane oxygenation, high-frequency oscillatory ventilation or any form of extra-corporeal lung support.
  • Subjects with history of any type of .
  • Major trauma in the prior 5 days.
  • Subjects with major surgery (body organs that require anesthesia, such as tumor removal, open chest, heart surgery, abdominal surgery, intracranial surgery, or normal surgery for more than 3 hours, etc.) within previous 14 days.
  • Subjects who are pregnant (or plan to become pregnant within 3 months of product treatment) or lactating.
  • Subjects who have a significant concomitant illness as judged by principal investigator (PI).
  • Subjects who have significant abnormal laboratory tests at screening:

    1. >5 × for (ALT) or aspartate aminotransferase (AST).
    2. >3 × upper limit of normal for total .
    3. >2 × upper limit of normal for serum creatinine.
  • Subjects with known infection or who are immune compromised.
  • Subjects who are unable to return for follow-up visits for clinical evaluation, laboratory studies, or imaging evaluation.
  • Subjects with a history of severe allergic or anaphylactic reactions.
  • Subjects with known allergy or to any component of the formulation (normal saline and human serum albumin).
  • Subjects who have participated in another clinical study of new investigational therapies or have received an investigational therapy within the 12 weeks before study drug administration.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    UMC119-06

    Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.

    Biological: UMC119-06

Interventions

  • BiologicalUMC119-06

    Cohort 1: Low does of UMC119-06;Cohort 2: Medium does of UMC119- 06;Cohort 3: High does of UMC119-06

06

What researchers measure

Primary outcomes

  1. The incidence and frequency of adverse events related to administration of UMC119-06.

    Incidence of Treatment-Emergent Adverse Events (TEAEs). Incidence of withdrawals due to AEs.

    Time frame: 3 months from the day of administration

Secondary outcomes

  1. Changes in mortality status

    Improvement in mortality status.

    Time frame: 15 months from the day of administration.

  2. Ventilator Free Days (VFD)

    Improvement in clinical function as assessed by Ventilator Free Days (VFD).

    Time frame: 28 days from the day of administration

  3. Change in Oxygenation Index (OI)

    Improvement in clinical function as assessed by change in Oxygenation Index (OI).

    Time frame: 7 days or discharge from ICU after the day of administration

  4. Change in Lung Injury Score (LIS)

    Improvement in clinical function as assessed by change in Lung Injury Score (LIS), 0-16 points, severity increasing with higher points.

    Time frame: 7 days or discharge from ICU after the day of administration

  5. Change in positive end-expiratory pressure (PEEP)

    Improvement in clinical function as assessed by change in positive end-expiratory pressure (PEEP).

    Time frame: 7 days or discharge from ICU after the day of administration

  6. Change in Lung Static Compliance

    Improvement in clinical function as assessed by change in Lung Static Compliance

    Time frame: 7 days or discharge from ICU after the day of administration

  7. Change in acute physiology and chronic health evaluation score (APACHE II)

    Improvement in clinical function as assessed by change in acute physiology and chronic health evaluation score (APACHE II), higher scores correspond to more severe disease and a higher risk of death.

    Time frame: 7 days from the day of administration

07

Study locations

1 site
  • Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare.
    New Taipei City, 23561, Taiwan
    • Claire Liao · ContactClaire.Liao@meridigen.com · +886-2-8978-7777
    • Joseph Chen · Contactjoseph.chen@meridigen.com · +886-2-8978-7777
    • Kang-Yun Lee · Principal investigator
    • Kuan-Yuan Chen · Sub investigator
    • Tzu-Tao Chen · Sub investigator
    • Yen-Han Tseng · Sub investigator
    • Chien-Hua Tseng · Sub investigator
    • Po-Hao Feng · Sub investigator
    • Wen-Te Liu · Sub investigator
    • Ching-Shan Luo · Sub investigator
    • Yun-Kai Yeh · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2024; primary completion for Sep 2024, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2020
First posted
Apr 15, 2020
StartEst.
Jan 1, 2024
Primary completionEst.
Sep 2024
CompletionEst.
Sep 2025
Last update
Dec 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04347967
Lead sponsor
Meridigen Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Apr 15, 2020
Start date
Jan 1, 2024 (estimated)
Primary completion
Sep 2024 (estimated)
Completion
Sep 2025 (estimated)
Last update
Dec 4, 2023

Study contacts

Claire Liao
Contact
claire.liao@meridigen.com
+886-2-8978-7777 ext. 19965
Joseph Chen
Contact
joseph.chen@meridigen.com
+886-2-8978-7777 ext. 19905

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion